PTU - Polskie Towarzystwo Urologiczne
list of articles:

Early toxicity of combined treatment in localised and locally advanced prostate cancer: hormone therapy with conformal radiotherapy
Article published in Urologia Polska 2002/55/2.


Piotr Milecki 1, Grażyna Stryczyńska 1, Tomasz Stachowski 2, Zbigniew Kwias 2
1 Department of Radiotherapy, Wielkopolskie Cancer Centre, Poznań, Poland, Head of the Department: Grażyna Stryczyńska, PhD, MD.
2 Chair of Urology, University School of Medical Sciences, Poznań, Poland, Chair of Urology: Zbigniew Kwias, PhD, MD


prostate - prostate cancer, radiotherapy i hormone therapy, acute morbidity


Purpose: to evaluate acute toxicity of combined treatment (androgen ablation and 3D confomial radiotherapy [3D-CRT]) in patients with localised and locally advanced cancer of the prostate.
Materials and methods. Between April 1999 and December 2000, at the Wielkopolskie Cancer Centre in Poznań, 42 patients with prostate cancer (T1-T3 NO MO) were treated with 3 D conformal radiation therapy and hormone therapy. Patients represented a localised disease (1=4 patients, T2 = 11 patients) and locally advanced disease (T3 = 27 patients). No patients had clinically detectable distant metastases. Neoadjuvant androgen ablation therapy (LH-RH agonists or bilateral orchidectomy and flutamide) was given to all patients. Radiotherapy was performed using 15 MV photons in the daily fraction of 1.8 Gy to the total median dose of 71.7 Gy (range, 67.8 to 72 Gy). Acute toxicities were evaluated according to the Radiation Therapy Oncology Group (RTOG) morbidity scoring scale.
Results. All patients completed the entire course of radiotherapy and were assessable for evaluation of acute toxicities. The most common side effects of androgen ablation were „hot flushes\", gynaecomastia, and slight discomfort in the abdomen, although these were of mild intensity. The main problems during irradiation and for a few weeks after the completion of radiotherapy were related to:
genito-urinary tract (rgency, nocturia, dysuria). Toxicities were as follow: grade 0 and 1: 80% of patients and grade 2: 20% of patients,
- gastro-inlestinal tract (ectal discomfort and mild diarrhoea). Toxicities were as follow: grade 0 and 1: 75% of patients and grade 2: 25% of patients.
Conclusions. Preliminary results of combined treatment (androgen ablation and 3- D CRT) suggested that such modality is well tolerated with only modest acute toxicities of gastro-intestinal and genito-urinary tract.


  1. 1. Zatoński W: Nowotwory złośliwe w Polsce. Centrum Onkologii, Warszawa 1993; 105-106.
  2. 2. American Society for Therapeutic Radiology and Oncology Consensus Panel: statement: Guidelines for PSA following radiation therapy. Int J Radial Oncol Biol Phys 1997; 37:1035-1041.
  3. 3. Hanks GE, Hanlon A. L, Schultheiss TE et al: Dose escalation with 3 D confoimal treatment: Jive year outcomes, treatment optimization and future directions. Int J Radiat Oncol Biol Phys 1998; 4: 501-510.
  4. 4. Hanks GE, Hanlon AL, Pinover WH el al: Survival advantage for prostate cancer patients treated with high-dose three-dimensional confoimal radiotherapy. Cancer J Sci Am 1999; 5:152-158.
  5. 5. Zelefsky MJ, Lyass O, Fuks Z et al:Locally advanced prostatic cancer: predictors of improved outcome for patients with localized prostate cancer treatment with neoadjuvant androgen ablation therapy and three-dimensional confoimal radiotherapy. J Clin Oncol 1998; 16: 3380-3385.
  6. 6. Bolla M, Gonzalez D, Warde P, et al:Improved survival inpatients with locally advanced prostate cancer treated with radiotherapy andgoserelin. N Engl J Med 1997; 337:295-300.
  7. 7. Pilepich MV, Sause WT, Shipley WU el al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616-623.
  8. 8. Pollack A, Zagars GK, Rosen II:Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity. Semin Oncol 1999; 26: 150-161
  9. 9. Roach M: Comparison of treatment techniques for confoimal radiotherapy of the prostate using dose-volume histograms and nomial tissue complication probabilities. Radiother Oncol 1996; 40: 85-87.
  10. 10. Hanks GE, Schulthesis TE, Hanlon AL: Optimization of confoimal radiation treatment of prostate cancer: Report of a dose escalation study. Int J Radiat Oncol Biol Phys 1988; 15: 1299-1305.
  11. 11. Zagars GK, Pollack A, Smith LG:Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, Nx/NO, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 1: 809-8.
  12. 12. Laverdiere J, Gomez JL, Cusan L et al: Beneficial effect of combination therapy administered prior to and following external beam radiation therapy in localized prostate cancer. Jnt J Radial Oncol Biol Phys 1997; 37:247-252.
  13. 13. Pilepich MV, Krall JM, Al-Sarraf M et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostate carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616-623.
  14. 14. Yang FE, Chen GTY, Ray P, et al: The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in confoimal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33:1009-1017.
  15. 15. Stiil GG: Basic clinical radiobiology - second edition, 1997. Oxford Univeristy Press, Inc. pp 132-141.
  16. 16. Zietman AL, Shipley WU: Androgen deprivation and radiation therapy prostate cancer: The evolving case for combination therapy. Int J Radiat Oncol Biol Phys 1993; 64:583-591.
  17. 17. Pollack A, Zagars GK: External beam radiotherapy dose response of prostate cancer. Jnt J Radiat Oncol Biol Phys 1997; 39: 1011-1018.
  18. 18. Pickett B, Vigneault E, Kurhanewicz J el al: Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999; 1: 921- 929.
  19. 19. Asbell SO, Krall JM, Pilepich MV et al: Elective pelvic irradiation in stage A2 and B carcinoma of prostate: analysis of RTOC, 77-06. Int J Radiat Oncol Biol Phys 1988; 15: 1307-1309.
  20. 20. Stock RG, Ferrari AC, Stone NN:Dose pelvic irradiation play a role in the management of prostate cancer? Oncology1998; 12: 1475-1476.
  21. 21. Rangala N, Cox JD, Byhardl RW el al:Local control and su-ivival after external irradiation for adenocarcinoma of the prostate. Int J Radiat Oncol BiolPhys 1982; 8:1909-1914.
  22. 22. Ploysongsang S, Aron BS, Shehata WM et al: Comparison of whole pelvis versus small-field radaiation therapy for carcinoma of prostate. Urology 1986; 27:10-16.
  23. 23. Storey RM, Pollack A, Zagars G et al: Complications from radiotherapy dose escalation in prostate in prostate cancer: preliminaiy results of a randomized trial. Int J Radiol Oncol Biol Phys 2000; 48: 635-642.
  24. 24. Pilepich MV Krall JM. Sause WT et al: Correlation of radio-therapeutic parameters and treatment related morbidity in carcinoma of the prostate- analysis of RTOG study 75-06. Inl J Radiat Oncol Biol Phys 1987; 13:351-357.
  25. 25. Soften EM, Hanks GE, Hunt MA et al:Confomial static-field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. Int J Radial Oncol Biol Phys 1992; 24: 485- 488.
  26. 26. Hanks GE, Schulthiess TE, Hunt MA et al: Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Inl J Radial Oncol Biol Phys 1995; 28: 55-65.
  27. 27. Conell PP, Ignacio L, McBride R. et al: Caution in interpreting biochemical control rales after treatment of prostate cancer: Length of follow-up influences results. Urology 1999; 54:875-879.
  28. 28. Critz FA, Levinson AK, Williams WH et al: Prostate specific antigen nadir:the optimum level after iiradiation for prostate cancer. J Clin Oncol 1996; 14:2893-2900.


Piotr Miiecki
ul. Modlińska 8
61-049 Poznań
tel.: (0-61) 854 05 35: 0 607 638 442
fax: (0-61) 852 19 48.